Ipsen discontinuing four-month formulation of Decapeptyl

Ipsen (Euronext:IPN) will discontinue an open-label, single-arm Phase III trial

Read the full 105 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE